Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

BACKGROUND: The phase 2b proof-of-concept Antibody Mediated Prevention (AMP) trials showed that VRC01, an anti-HIV-1 broadly neutralising antibody (bnAb), prevented acquisition of HIV-1 sensitive to VRC01. To inform future study design and dosing regimen selection of candidate bnAbs, we investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Seaton, Kelly E., Huang, Yunda, Karuna, Shelly, Heptinstall, Jack R., Brackett, Caroline, Chiong, Kelvin, Zhang, Lily, Yates, Nicole L., Sampson, Mark, Rudnicki, Erika, Juraska, Michal, deCamp, Allan C., Edlefsen, Paul T., Mullins, James I., Williamson, Carolyn, Rossenkhan, Raabya, Giorgi, Elena E., Kenny, Avi, Angier, Heather, Randhawa, April, Weiner, Joshua A., Rojas, Michelle, Sarzotti-Kelsoe, Marcella, Zhang, Lu, Sawant, Sheetal, Ackerman, Margaret E., McDermott, Adrian B., Mascola, John R., Hural, John, McElrath, M. Julianna, Andrew, Philip, Hidalgo, Jose A., Clark, Jesse, Laher, Fatima, Orrell, Catherine, Frank, Ian, Gonzales, Pedro, Edupuganti, Srilatha, Mgodi, Nyaradzo, Corey, Lawrence, Morris, Lynn, Montefiori, David, Cohen, Myron S., Gilbert, Peter B., Tomaras, Georgia D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363420/
https://www.ncbi.nlm.nih.gov/pubmed/37300931
http://dx.doi.org/10.1016/j.ebiom.2023.104590

Ejemplares similares

Ejemplares similares